Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels

摘要

Disclosed is a method of predicting a likelihood that an EFGR expressing colorectal cancer will respond to treatment with an EGFR inhibitor. A sample of the tumor is analysed for the expression levels of genes AREG, EREG, DUSP6 and SLC26A3 with higher levels of AREG, EREG and SLC26A3 indicating the patient will benefit from treatment with an EGFR inhibitor and higher levels of DUSP6 being negatively correlated with a beneficial response.